Biopharma Stock Updates - 12/09/20

Data Updates:

$GMDA (-13.3%) – Topline phase 3 results & BLA plans

https://investors.gamida-cell.com/news-events/press-releases/news-release-details/gamida-cell-provides-pipeline-update-including
 

$CYTK (+22.8%) – Phase 2 interim analysis – proceed to cohort 2

https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-progression-redwood-hcm-cohort-2
 

$ATNX (-3.3%) – Updated phase 3 data for oraxol

https://ir.athenex.com/news-releases/news-release-details/athenex-presents-updated-phase-3-data-survival-and-tolerability
 

$EDIT (+17%) – Submitted IND for EDIT-301 in SCD

https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-submission-ind-application-edit-301
 

$FPRX (-12.5%) – Will present phase 2 data at ASCO 01/15/21

https://investor.fiveprime.com/news-releases/news-release-details/five-prime-present-phase-2-fight-trial-results-bemarituzumab
 

$GTHX (-7.5%) – Phase 2 data for Triliciclib and phase 1 update

http://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-presents-final-phase-2-clinical-data-trilaciclib
 

Financial:

$KURA (-1.2%) – Priced their offering at $37/share

https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-announces-pricing-300-million-public-offering
 

$SNDX (+7%) – Priced their offering at $23/share

http://ir.syndax.com/news-releases/news-release-details/syndax-announces-pricing-public-offering-common-stock-0
 

$MIRM (+0.67%) - $210 million funding arrangement – tiered revenue-based

https://mirumpharma.gcs-web.com/news-releases/news-release-details/mirum-pharmaceuticals-and-oberland-capital-announce-210-million